NGL Fine-Chem Limited (NGLFINE.BO)

INR 2040.15

(2.62%)

Operating Expenses Summary of NGL Fine-Chem Limited

  • NGL Fine-Chem Limited's latest annual operating expenses in 2023 was 816.16 Million INR , down -28.86% from previous year.
  • NGL Fine-Chem Limited's latest quarterly operating expenses in 2024 Q1 was 223.14 Million INR , down -9.07% from previous quarter.
  • NGL Fine-Chem Limited reported a annual operating expenses of 1.14 Billion INR in annual operating expenses 2022, up 1.5% from previous year.
  • NGL Fine-Chem Limited reported a annual operating expenses of 1.13 Billion INR in annual operating expenses 2021, up 48.09% from previous year.
  • NGL Fine-Chem Limited reported a quarterly operating expenses of 245.38 Million INR for 2023 Q4, down -31.4% from previous quarter.
  • NGL Fine-Chem Limited reported a quarterly operating expenses of 816.16 Million INR for 2023 FY, down -28.86% from previous quarter.

Annual Operating Expenses Chart of NGL Fine-Chem Limited (2023 - 2007)

Historical Annual Operating Expenses of NGL Fine-Chem Limited (2023 - 2007)

Year Operating Expenses Operating Expenses Growth
2023 816.16 Million INR -28.86%
2022 1.14 Billion INR 1.5%
2021 1.13 Billion INR 48.09%
2020 763.31 Million INR 7.97%
2019 706.97 Million INR 20.56%
2018 586.38 Million INR 21.98%
2017 480.72 Million INR 34.54%
2016 357.31 Million INR -1.4%
2015 362.39 Million INR 4.67%
2014 346.21 Million INR 17.02%
2013 295.87 Million INR 38.35%
2012 213.86 Million INR 42.15%
2011 150.45 Million INR 4.92%
2010 143.39 Million INR 2637.32%
2009 5.23 Million INR -10.34%
2008 5.84 Million INR -91.0%
2007 64.91 Million INR 0.0%

Peer Operating Expenses Comparison of NGL Fine-Chem Limited

Name Operating Expenses Operating Expenses Difference
Abbott India Limited 5.98 Billion INR 86.366%
Cipla Limited 59.21 Billion INR 98.622%
Gland Pharma Limited 3.86 Billion INR 78.865%
GlaxoSmithKline Pharmaceuticals Limited 4.35 Billion INR 81.269%
Kopran Limited 859.54 Million INR 5.047%
Marksans Pharma Limited 3.28 Billion INR 75.188%
Pfizer Limited 4.33 Billion INR 81.182%
Sanofi India Limited 3.69 Billion INR 77.9%
SMS Pharmaceuticals Limited 370.89 Million INR -120.054%